CTLA4 and cancer: In this case, ICBs targeting PD-L1 may reach maximal efficacy in inhibiting the cell-autonomous pro-metastatic effects of PD-L1 in the cancer cells if they will be given alongside ICBs that prevent immune suppression by targeting PD-1 or CTLA-4.